Our Focus
At PharmaEssentia, we are focused on providing new best-in-class therapeutic science for patients with myeloproliferative neoplasms (MPNs) and other hematologic cancers.
Myeloproliferative neoplasms are a group of rare, chronic blood cancers that develop from a mutation in the stem cells. Patients with MPNs have historically had limited treatment options, and these diseases can result in chronic symptom burden, risk of health complications, including progression to more aggressive forms of cancer.
Our researchers are working diligently to provide physicians and patients with tolerable, effective, long-term treatments that aim to improve patient outcomes and reduce the risk of disease progression.
There are several types of MPNs, each with unique characteristics and challenges. We’re working to develop solutions across the full range of these rare blood cancers.
Polycythemia vera (PV) is characterized by the overproduction of red blood cells, which can increase blood viscosity and raise the risk of blood clots. Learn about our FDA-approved product for PV.
ET is characterized by the overproduction of platelets (thrombocytes), which can cause possible thrombotic and hemorrhagic complications.
Primary myelofibrosis (PMF) is a rare, chronic blood cancer in which abnormal stem cells in the bone marrow cause scar tissue (fibrosis), disrupting normal blood cell production. PMF leads to anemia, low or high white blood cell counts, abnormal platelets, and symptoms such as fatigue, night sweats, weight loss, and enlarged spleen (splenomegaly). The disease is classified as a myeloproliferative neoplasm and is often associated with mutations in the JAK2 gene. The disease can lead to aggressive cancers such acute myeloid leukemia (AML).
A Phase 3, open-label, multicenter, randomized, active-controlled trial assessing the efficacy, safety, tolerability, and pharmacokinetics of ropeginterferon alfa-2b after 12 months of treatment compared with anagrelide (ANA) as second-line therapy for adult patients with ET who have shown resistance or intolerance to hydroxyurea (HU).
A Phase 2b, single-arm, multicenter trial assessing the efficacy, safety, and tolerability of ropeginterferon alfa-2b in adult patients with ET in the US and Canada.
A Phase IIIb, Randomized, Open-Label, Parallel Group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon alfa-2b-njft (P1101) in Adult Patients with Polycythemia Vera (PV).
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Study to Assess Efficacy and Safety of Ropeginterferon Alfa-2b (P1101) in Adult Patients With Pre-fibrotic/Early Primary Myelofibrosis (PMF) or Overt PMF at Low or Intermediate-1 Risk According to DIPSS Plus.
Access the latest scientific and clinical data from PharmaEssentia
Polycythemia Vera (PV)
Essential Thrombocythemia (ET)
Other Myeloproliferative Neoplasms (MPNs)
To Learn More, Visit PharmaEssentia Medical Affairs
